Suzhou Fushilai Pharmaceutical (301258.SZ) intends to jointly establish a partnership with Longju Dongfang and others to invest in strategic emerging industries that meet the requirements of new productive forces development.

Suzhou Fushilai Pharmaceutical (301258.SZ) announced that its wholly-owned subsidiary, Suzhou Berger Zhiyuan Investment Management Co., Ltd. (hereinafter referred to as "Berger Capital"), intends to contribute 48 million yuan as a limited partner to jointly establish Suzhou Longju Dongge Entrepreneurship Investment Partnership Enterprise (Limited Partnership) with Suzhou Longju Dongfang Investment Management Enterprise (Limited Partnership) and Zhang Weidong. Berger Capital will account for 48.00% of the total subscribed capital. Longju Dongfang is a private equity venture capital institution that focuses on the Yangtze River Delta region and the fields of hard technology and biomedicine. On one hand, it deeply cultivates strategic emerging industries such as semiconductors, optical communications, new materials, and advanced manufacturing. On the other hand, it focuses on the pharmaceutical and health industry, covering APIs, innovative formulations, medical devices, health raw materials, and other sub-sectors, landing multiple high-quality pharmaceutical projects, and is dedicated to promoting innovation and upgrading of the biopharmaceutical industry and the development of high-growth enterprises. Leveraging industry resources and professional teams, it focuses on investing in high-quality companies in the growth period to pre-IPO stage. Listed projects include Brightgene Bio-Medical Technology Co., Ltd., Suzhou Xianglou New Material, Xiamen UX IC, Goode EIS, as well as representative projects such as Weikang Probiotics, Tiejin Technology, and Suzhou Keyang. The partnership established this time focuses on investing in strategic emerging industries that meet the requirements of new quality production, with investment stages mainly in the growth period, expansion period, and pre-IPO stage.